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ciency among six distinct hybrid algorithms used with health care
data. METHODS: Six matching algorithms were examined. Each
combined covariate matching with a different propensity scoring
function: continuous factor, weighting factor, caliper, parenting
factor, nesting factor or partner. The algorithms were compared in
terms of 1:1 matching rate, computing time, bias balancing and
standardized difference. The inﬂuence of sample size variation on
stability and efﬁciency was considered. Paired T-test, Pearson
Chi-Square and Standardized Difference were adopted for assess-
ment. RESULTS: The superiority of some hybrid algorithms over
pure covariate matching was observed. In terms of matching rate,
the partner function reported the highest rate (99.7%), followed
by its function as a caliper (88.4%), while the parenting function
produced the lowest rate (59.5%). All others performed at a
similar level. Computing time varied, the most efﬁcient using the
propensity score as a parenting factor (00:25:10). The longest
reported times were seen when used as a weighting factor
(00:37:56) or caliper function (00:37:52). Differences are more
profound in large samples. In bias balancing tests, all algorithms
were balanced on categorical covariates except when the propen-
sity score was used as a partner or a caliper where each displayed
the lowest capability of producing p-values above 0.05. Signiﬁcant
reduction in standardized difference below 10% was indicative of
higher efﬁciency of the hybrid algorithms. Categorical covariates
produced values near zero despite the lower performance for the
partner approach. With increasing sample size, all investigations
performed as expected. CONCLUSION: Overall, these hybrid
applications exhibited greater efﬁciency in simultaneously over-
coming high dimensionality on covariate matching and reducing
variation in propensity score matching. Depending on data char-
acteristics and research proﬁles, each application has speciﬁc
merits in certain circumstances.
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SETTINGTHE OPTIMAL SCREENINGTOOLTHRESHOLD FOR
A CHRONIC UNDERDIAGNOSED ILLNESS:WHOSE BURDEN
MATTERS MOST?
Yu HT, Calimlim B, Dean BB, Dubois R
Cerner LifeSciences, Beverly Hills, CA, USA
Ankylosing spondylitis (AS) is a chronic disease with approxi-
mately 0.5% prevalence in the general population and 5%
among chronic back pain (CBP) sufferers. The disease typically
remains undiagnosed for over a decade which is problematic
since new treatments may alter the natural history. An AS screen-
ing instrument based upon patient reported data was developed
but selecting the optimal screening tool threshold is a critical
issue for discussion. Question items were identiﬁed from a litera-
ture review, patient focus groups, and an advisory board of
rheumatologists. A case-control study was conducted to test the
screening instrument among subjects with conﬁrmed AS (cases)
or CBP for3 months (controls). Question items were examined
in a multivariate logistic framework using best subsets modeling.
Receiver-operator characteristic analysis was conducted to deter-
mine optimal sensitivity (SE), speciﬁcity (SP), positive predictive
value (PPV), and negative predictive value (NPV) of the instru-
ment: AS prevalence set equal to 0.5% in the general population
and 5% among CBP sufferers. Responses from 102 cases and 214
controls were analyzed to develop a twelve-variable model. Sen-
sitivities ranging from 69.6% to 90.2% were associated with
speciﬁcities of 99.1% to 79.9%, respectively. Lowering sensitivi-
ties reduced the portion of false positives seen by the provider
from 95% to 20.3% (78.6% reduction) and 99.5% to 72.8%
(26.8% reduction) for the CBP and general populations, respec-
tively (SE = 69.6%, SP = 99.1%). Selecting the optimal screening
tool threshold depends on whose burden matters the most:
increasing sensitivity of the instrument would increase the prob-
ability of identifying patients with disease earlier and the ability
to improve AS patient well-being. However, this approach would
increase the economic burden (additional medical evaluations)
from the payer perspective, raise the patient care burden from the
rheumatologist perspective, and reduce quality of life for those
with false positives. We will discuss the trade-offs in this real
world example.
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TRANSLATING HETEROGENEITY BIAS FROM HEALTH
STATUS IN OUTCOMES STUDIES—USING LATENT CLASS
CLUSTER ANALYSIS AND LONGITUDINAL DATA
Ahn J
University of Southern California, Los Angeles, CA, USA
Ignoring heterogeneity in health may bias measurement of
intervention outcomes through confounding with intervention
of interest. If repeated observations on each subject are avail-
able, heterogeneity may be usefully included in outcomes
studies. We assume heterogeneous health status as a latent
index and multiple health proxies (and their correlations) are
used to estimate heterogeneous health grouping from the latent
index. For example, in a treatment effect study with longitudi-
nal data: 1) estimate K, the number of heterogeneous groups,
by latent class cluster analysis (LCCA) using health proxies of
each subject at each period, such as comorbidity indices, length
of hospitalization, total health care cost and so on; 2) if K > 1
(heterogeneity), estimate a treatment effect for each group and
compare the results across the groups; 3) if the effects vary over
the groups, heterogeneity can be translated by each group’s
health proﬁle (e.g. higher effectiveness found in sick but less
hospitalized group). This approach is relatively conservative
and combines multiple proxies objectively. Estimating K implies
a near consensus of model selection criteria such as Bayesian
Information Criteria (BIC), adjusted BIC, Akaike Information
Criteria (AIC), and consistent AIC; and bootstrap likelihood
ratio test (BLRT). Furthermore, it is difﬁcult to ﬁnd a practi-
cally useful K (say <5) because K tends to diverge to N (i.e.
each subject is a group), for a large enough sample size N.
Applying heterogeneity estimation to a claims data of 3260
subjects for two years found two heterogeneous groups (BIC,
adjusted BIC, consistent AIC, and BLRT all supported K = 2
except AIC). One group (N = 2841) was signiﬁcantly sicker
than the other group (N = 419) in Year 1 (and in Year 2) at
5%: Charlson Comorbidity Index 3.91 vs 0.11 (4.49 vs 0.14);
length of stay 0.87 vs 0.03 (1.04 vs 0); total cost $10690 vs
$245 ($11149 vs $184).
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Rindress D
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Develop a quantitative and practical methodology to structure,
objectify and facilitate health care decisionmaking. A concep-
tual framework was developed that segregated components of
decision-making into three categories: 1) quality of evidence
available; 2) intrinsic value of the health care intervention; and 3)
extrinsic or system related value, usually not directly quantiﬁ-
able. Using this framework, practical tools to assess health care
interventions were designed drawing on an extensive review of
the literature and of current decisionmaking processes for drug
reimbursement around the world. A matrix to quantify the
quality of evidence available for a health care intervention was
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designed including 5 elements deﬁning quality, clustered into
three criteria, and 12 components covering types of evidence
required by decision-making bodies worldwide. A scoring
process was developed based on international scientiﬁc standards
in each ﬁeld of research covered. To quantify the intrinsic value
of an intervention, a multi-criteria decision analysis (MCDA)
matrix was designed encompassing 15 value components.
Scoring, which depends on the value system of the evaluator, was
designed to allow inclusion of perspectives of a representative
group of health care stakeholders. An integrated process to apply
matrices was established. The EVIDEM methodology can be
applied retrospectively to explore the contribution of quality of
evidence and intrinsic value to past coverage decisions. Prospec-
tively, matrices can be adapted to speciﬁc needs of decision-
makers and applied to evaluate new health care interventions.
The matrices also provide a practical collaborative frame-
work for those who generate data and those who need data
to make decisions, ultimately facilitating future health care
decision-making.
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Adherence is an important element in the medical ﬁeld since it is
thought to be the link between treatment and outcomes. Adher-
ence to medications has been extensively researched and it is
evident that non-adherence is common across most disease
states. These studies vary by the conceptual deﬁnitions of adher-
ence behavior and by the research paradigms. The objectives of
this presentation are to review the conceptual deﬁnitions used in
adherence research and to review the theoretical frameworks
used to explain mediation adherence behavior. Compliance,
adherence, and concordance are used interchangeably in the
medical, health behavior, and pharmacy literature. It is important
to compare and contrast these terms to study speciﬁc health
behavior. These terms reﬂect different philosophies of medicine
with respect to the provider-patient relationship. Conceptually,
adherence, compliance and concordance differ in the amount of
patient involvement and participation, that may be depicted
along a continuum of patient involvement- with compliance
depicting no patient involvement, concordance depicting patients
as being equal partners in their treatment and adherence lying
somewhere in between. Consistent use of these concepts will
move the science toward understanding speciﬁc patient behavior
and its antecedents.
Much of the adherence research published in the medical and
pharmacy journals does not include a theoretical framework.
The non-theoretical approach to adherence research is partly to
blame for the lack conceptual clarity and underscores the need to
incorporate a theoretical basis in adherence research. Prominent
theories in adherence research include expectancy-values models
like the health belief model, the transtheoretical model, and the
self-regulation theory. Other promising models include the medi-
cation adherence model, the interaction model of client behavior
and the therapeutic decision model. The strengths and weak-
nesses of each are presented. Finally, recommendations for
researchers of medication adherence include using a theoretical
framework and conducting longitudinal studies are provided.
PMC52
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OBJECTIVE: Clinical evidence is often reported as an average
treatment effect across a large population. This is appropriate if
all patients experience the same effect from a given treatment.
However, more often, different patients experience different
outcomes on the same medication. If this is true, then averaging
the effects of treatment obscures the outcomes received by most
patients. It also makes it difﬁcult for physicians to utilize this
evidence to select the most appropriate treatment for individual
patients. This interpretation of average outcomes by physicians
leads to geographic variation, inappropriate care, and increased
health care costs. An essential step towards optimizing therapy
is to provide evidence that recognizes inter-individual differ-
ences in drug response. METHODS: The PPS is deﬁned as the
expected outcome (on control) given the individual’s covariates.
To calculate the PPS, the outcome of interest is regressed on the
covariates for those patients treated with the control(Drug A).
Using the coefﬁcients from this model, in conjunction with
patient characteristics, the PPS is computed for all patients; as
if every patient was a member of the control group. Variations
in treatment effect are then identiﬁed across subgroups by par-
titioning patients, according to PPS, into strata and calculat-
ing the treatment effect within each stratum. This analysis
is repeated using the alternative treatment (Drug B) as the
control. By identifying and comparing the stratum that receives
the optimal beneﬁt from each treatment, the patient character-
istics that are uniquely associated with success on Drug A and
Drug B can be determined. RESULTS: To demonstrate the use
of the PPS, a convenient sample of California Medicaid beneﬁ-
ciaries diagnosed with schizophrenia will be used. CONCLU-
SIONS: The outlined approach will allow physicians to more
accurately prescribe the most beneﬁcial treatment for each and
every patient, by linking patient characteristics to treatment
success.
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PREVALENCE OF RESEARCH FOCUSED ON
GENETICALLY-LINKED DISORDERS:WHERE HAVEWE
BEEN ANDWHERE AREWE GOING?
Samuels E, Lock K, Karia R, Stoddart SD
Heron Evidence Development Ltd, Letchworth Garden City,
Hertfordshire, UK
OBJECTIVES: The completion of the human genome project
has not provided the answer to genetic disease that was
expected and a large amount of research is still being con-
ducted into the treatment of genetically-linked disorders. The
rationale of this review was to investigate the proportion of
research conducted within eight genetically-linked disorders
across time (Alzheimer’s disease [AD], Crohn’s disease [CD],
cystic ﬁbrosis [CF], haemophilia, Huntington’s disease [HD],
muscular dystrophy [MD], Obesity, Sickle cell anaemia [SCA])
and to predict likely areas of growth within the selected disor-
ders. METHODS: A citation search was conducted in Medline
on December 12, 2007. A ﬁlter for RCTs was implemented to
provide an estimate of clinical interest in a given disease for the
years 1951–2005 (5-yearly time periods). RESULTS: A total of
706,660 probable RCT citations were retrieved, with 20,787
relating to the selected disorders. Over time, the rate of increase
of probable RCTs relating to these genetically-linked disorders
is not signiﬁcantly different from the general increase in RCTs
A184 Abstracts
